Topic background: Applied Life Sciences & Health →

Cerebrospinal fluid drainage from the brain into the body is necessary to remove metabolic waste from the brain. The flow declines with age, and evidence strongly suggests that this is an important contribution to the build up of protein aggregates and other waste that drive the onset and development of neurodegenerative conditions. Much of the focus is on the glymphatic system of vessels at the b

Topic background: Applied Life Sciences & Health →

A number of prevalent age-related conditions are notably different in timing and progression between the sexes. No doubt the list of differences by sex will grow as the research community explores the first therapies that target important mechanisms of aging. Here, researchers report on an attempt to treat intervertebral disc degeneration in mice using a senolytic drug that selectively destroys th

Topic background: Applied Life Sciences & Health →

Senescent cells accumulate with age and contribute to degenerative aging via their pro-growth, pro-inflammatory signaling. Even when less than 1% of all cells are senescent in a tissue, the signaling generated by those senescent cells alters the behavior of other cells for the worse, and is disruptive to tissue structure and function. When it comes to what to do about the burden of senescent cells

Topic background: Applied Life Sciences & Health →

In Aging Cell, researchers have published an explanation of how neutrophil extracellular traps (NETs) worsen UVB damage and how inhibiting them alleviated this damage in a mouse model. When defenders just make […]

Topic background: Applied Life Sciences & Health →

Montana’s first experimental treatment review board has brought three longevity heavyweights into the state’s effort to expand access to experimental therapies. How much regulation is too much? Many people in the longevity […]

Topic background: Applied Life Sciences & Health →

A team of researchers has concluded that while methylation-based epigenetic clocks generally give reliable outputs when given the same inputs, short-term biological fluctuations can drastically change […]

Topic background: Applied Life Sciences & Health →

As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…

Topic background: Applied Life Sciences & Health →

Nature, Published online: 31 July 2026; doi:10.1038/d41586-026-02362-2The allergy is caused by ticks, but researchers have much to learn about it.

Topic background: Applied Life Sciences & Health →

Nature, Published online: 03 August 2026; doi:10.1038/d41586-026-02398-4Bispecific antibodies, which bind to two targets, are sweeping into the clinic and are prompting even more elaborate versions.

Topic background: Applied Life Sciences & Health →

Nature, Published online: 03 August 2026; doi:10.1038/d41586-026-02339-1A combination of drugs restores stem-cell function in mouse models of the blood disorder.

Topic background: Applied Life Sciences & Health →

Treatment with neural stem cells — cells that have the ability to mature into supportive cells of the brain and spinal cord — showed early signs of neuroprotection in people with progressive forms of multiple sclerosis (MS), according to long-term follow-up data from a small early clinical trial. The data show that the use of […] The post Stem cell treatment for progressive MS shows potentia

Topic background: Applied Life Sciences & Health →

Therapies to remove harmful immune B-cells that drive inflammation in multiple sclerosis (MS) may also work by mobilizing protective, gut-derived B-cells into the bloodstream and nervous system, a new study shows. Researchers also found that higher levels of molecules thought to drive such protective functions in B-cells were linked to better clinical outcomes in patients […] The post B-cell

Topic background: Applied Life Sciences & Health →

Following a Mediterranean-style diet may be associated with lower odds of multiple sclerosis (MS) onset, and diet-related differences in biological processes that regulate gene activity may partly help explain the association, a study in Australia has found. Specifically, differences in DNA methylation were estimated to account for up to about one-third of the association between […] The pos

Topic background: Applied Life Sciences & Health →

HSCT has to be the most effect immunomodulation as it aims to replace your immune system with chemotherapy to kill you immune systme and then HSCT replaces the lost cells. However there are issues with using it and people have to be aware that these drugs kill dividing things and that includes your eggs and […]

Topic background: Applied Life Sciences & Health →

As I am others have said many times it seems that the biology indicates that for most people rigid 6 monthly dosing with anti-CD20 infusion once disease is stabilised is probably overkill. As part of your health check people are often given scans and this paper asks do you have to scan yearly if you […]

Topic background: Applied Life Sciences & Health →

Ocrelizumab is licenced for relapsing and active primary progressive MS (Lesions and relapses) in the EU…It is active because we know it works by stopping B cells from entering the CNS to trigger lesions and relapses. Based on studies published years ago, even if people are on treatment then we are going to see progression. […]

Topic background: Applied Life Sciences & Health →

Nature has published a research study entitled The genetic architecture […] The post Research: A large international study on Fibromyalgia has identified potential risk factors across patients’ genes appeared first on The ME Association.

Topic background: Applied Life Sciences & Health →

Abstract: Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating, multi-systemic condition that has gained renewed global attention due to its ...

Topic background: Applied Life Sciences & Health →

Abstract: Fatigue, brain fog and post-exertional malaise are major features of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome and post-acute sequelae of ...

Topic background: Applied Life Sciences & Health →

Abstract: Introduction: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and long COVID have overlapping symptoms, such as profound fatigue, cognitive impairment, post-exertional malaise, ...

Topic background: Applied Life Sciences & Health →

Geoff’s Narration The GIST   Health Update – two weeks of mostly rest have been helpful 🙂 My concerning symptoms (cold sweats, nausea) are down substantially. Hopefully, a couple more weeks of rest will get me back to baseline. Note: neuroplasticity is another hot-button issue! Please respond as objectively as […] The post The Big Long COVID Neuroplasticity Trial: Did it Wor

Topic background: Applied Life Sciences & Health →

Jarred Younger’s face lit up in a recent YouTube video when he talked about a recent study long-COVID study: “Reduced Adenosine Triphosphate-to-Phosphocreatine Ratios in Neuropsychiatric Post-COVID Condition: Evidence From 31P Magnetic Resonance Spectroscopy“. The study used, for the first time in long COVID (or ME/CFS), a technique that measures energy availability […] The

Topic background: Applied Life Sciences & Health →

After seeing its lead candidate rejected by the FDA last year, Capricor Therapeutics is hoping for a better outcome for its resubmitted BLA for its lead pipeline candidate Deramiocel. The post StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel appeared first on GEN - Genetic Engineering and Biotechnology News.

Topic background: Applied Life Sciences & Health →

The collaboration is specifically focused on applying Receptor.AI's computational platform to Sethera's proprietary polymacrocyclic peptide chemistry, encoded screening data, and resulting therapeutic candidates. Each company will retain its background platform technologies. The post Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic Ta

Topic background: Applied Life Sciences & Health →

The first use of combined phage therapy and fecal microbiota transplantation for recurrent urinary tract infections reduced antibiotic use and improved quality of life in three women, supporting future clinical trials. The post Combined Phage Therapy and FMT Reduces Recurrent UTIs and Antibiotic Use in First Human Case Series appeared first on GEN - Genetic Engineering and Biotechnology News.

Topic background: Applied Life Sciences & Health →

A Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent cardiovascular complications.

Topic background: Applied Life Sciences & Health →

Medicare is removing flexibilities that have allowed "breakthrough" medical devices to leapfrog qualifications for extra payments.

Topic background: Applied Life Sciences & Health →

Latigo Biotherapeutics said its non-opioid drug reduced acute pain in a Phase 2b study, as the company seeks to compete with Vertex Pharmaceuticals’ approved pain treatment Journavx. Next, Latigo has to replicate its findings in ...

Topic background: Applied Life Sciences & Health →

An anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between cardiovascular inflammation and heart disease, the Danish company revealed Friday. The ...